Sort by
Refine Your Search
-
Listed
-
Program
-
Employer
-
Field
-
Postdoctoral position: Developing a human lymphoid organ-on-chip to evaluate candidate mRNA vaccines
A post-doctoral position is available to develop a 3D model of a human lymph node and apply this model to preclinical vaccine evaluation. The successful applicant will join the team of Lisa
-
The candidate will be in charge of developing clonal patient-derived organoid (PDO) models from resections. The candidate will be in charge of developing clonal patient-derived organoid (PDO) models
-
of teaching and research, the FSTM seeks to generate and disseminate knowledge and train new generations of responsible citizens in order to better understand, explain and advance society and environment we
-
of teaching and research, the FSTM seeks to generate and disseminate knowledge and train new generations of responsible citizens in order to better understand, explain and advance society and environment we
-
molecular targets critical for developing new therapies for rare diseases, based on genetic data and biological system simulations. -Computational Drug Repurposing: Developing novel algorithms and databases
-
generally to develop new distributed edge services. The successful candidate is expected to evaluate metrics such as latency, throughput, availability, and resilience in different applications scenarios
-
processes (development, immunity, stress responses, etc.). RNA stability regulation has been associated with the pathophysiology of various diseases [3–5]. This mechanism is especially important when rapid
-
Micha, Research Engineer at CNRS/ESRF, This Post-doctoral position focuses on the development of interpretable artificial intelligence methods for detecting and analysing anomalies in synchrotron beamline
-
available to work on computational models of artificial evolution for aptamer design, expected to start between November 2025 and February 2026. Aptamers are often obtained through rounds of in vitro
-
Background: The nuclear oncology team has a long-lasting expertise in the development of targeted alpha therapy and is internationally recognized for its research on astatine-211 labeling chemistry